Literature DB >> 21838308

Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.

Hamidreza Montazeri Aliabadi1, Breanne Landry, Parvin Mahdipoor, Hasan Uludağ.   

Abstract

Post-transcriptional silencing of antiapoptotic genes is a promising strategy for cancer therapy, but delivering short interfering RNA (siRNA) molecules against such targets is challenging due to inability of anionic siRNA to cross cellular membranes. Lipid substitution on small molecular weight, nontoxic polyethylenimine (PEI) has been investigated as a promising approach for effective siRNA delivery. In this study, we report on the ability of low molecular weight, lipid-substituted PEI to deliver siRNA against the antiapoptotic protein survivin. Toxicity of a library of lipid-substituted PEIs, as well as their siRNA delivery and survivin silencing efficiency, was evaluated in MDA-MB-231 human breast cancer cells. A significant increase in cellular delivery of siRNA was observed as a result of lipid substitution. Most significant downregulation of survivin was established by caprylic acid-substituted polymers, which resulted in significant levels of apoptosis induction and resultant loss of cell viability. Survivin downregulation prior to anticancer drug treatment decreased the IC(50) of several drugs by 50- to 120-fold. Our experiments indicated an effective downregulation of survivin, a cell protective protein upregulated in tumor cells, by delivering siRNA with hydrophobically modified PEI. This study introduces a promising delivery system for safe and effective siRNA delivery that will be suitable for further investigation in preclinical animal models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21838308     DOI: 10.1021/mp200176v

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  21 in total

1.  Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.

Authors:  Astrid Weiss; Boris Brill; Corina Borghouts; Natalia Delis; Laura Mack; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

2.  A survivin-associated adaptive response in radiation therapy.

Authors:  David J Grdina; Jeffrey S Murley; Richard C Miller; Helena J Mauceri; Harold G Sutton; Jian Jian Li; Gayle E Woloschak; Ralph R Weichselbaum
Journal:  Cancer Res       Date:  2013-05-07       Impact factor: 12.701

3.  Long double-stranded multiplex siRNAs for dual genes silencing.

Authors:  Wei Peng; Jianxin Chen; Yinchao Qin; Zhenjun Yang; York Yuanyuan Zhu
Journal:  Nucleic Acid Ther       Date:  2013-05-08       Impact factor: 5.486

Review 4.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

5.  Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.

Authors:  Daniel R Budman; Anthony Calabro; Lisa Rosen; Martin Lesser
Journal:  Anticancer Drugs       Date:  2012-03       Impact factor: 2.248

6.  Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.

Authors:  Samarwadee Plianwong; Bindu Thapa; Remant Bahadur Kc; Cezary Kucharski; Theerasak Rojanarata; Hasan Uludağ
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

Review 7.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

8.  An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).

Authors:  Xiang Ling; Fengzhi Li
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

Review 9.  Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective.

Authors:  Anubhav Jain; Saurabh Bundela; Ram P Tiwari; Prakash S Bisen
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

10.  A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Authors:  Xiang Ling; Shousong Cao; Qiuying Cheng; James T Keefe; Youcef M Rustum; Fengzhi Li
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.